Deucravacitinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Rosacea. According to GlobalData, Phase II drugs for Rosacea have a 38% phase transition success ...

Fostamatinib disodium is under clinical development by Rigel Pharmaceuticals and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Pneumonia.

Medically reviewed by Marisa Garshick, MD Laser hair removal is a safe and effective option for treating hidradenitis ...

Treatment involves avoiding the irritant and using creams or ointments to repair ... Shaving or waxing are common ways people ...

Medically reviewed by Brendan Camp, MD Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that causes ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks InflaRx ( (IFRX) ) has issued an update.

N.V.announced that the first patient has been dosed in its Phase 2a basket study in chronic spontaneous urticaria, CSU, and ...

JENA, Germany, Dec. 20, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory ...

BTIG analyst Julian Harrison initiated coverage of Avalo Therapeutics (AVTX) with a Buy rating and $40 price target The firm sees the company’s AVTX-009 as having best-in-class features that could ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that ...

Hidradenitis Suppurativa (HS) is a chronic inflammatory skin condition that disproportionately affects women and people of color. It begins in adolescence and can be debilitating, negatively impacting ...

The most-read obesity articles of 2024 mostly focused on insurance coverage of weight loss medications and costs.